Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7823315 | 0.81 | LMNA (0.67) | LMNAMAPTSMN1; SMN2ABCC4GAA | |
| SCHEMBL26688082 | 0.80 | LMNA (0.46) | LMNATSHRHTTSLC6A3 | |
| SCHEMBL26688084 | 0.79 | L3MBTL1 (0.51) | LMNAMAPTSMN1; SMN2GAATSHR | |
| SCHEMBL8713659 | 0.77 | TSHR (0.49) | LMNAMAPTSMN1; SMN2GAATSHR | |
| SCHEMBL26688078 | 0.77 | LMNA (0.43) | LMNAMAPTSMN1; SMN2GAA | |
| SCHEMBL26688071 | 0.76 | PDCD1 (0.47) | LMNAMAPTSMN1; SMN2GAATSHR | |
| SCHEMBL2653688 | 0.74 | TSHR (0.53) | LMNAMAPTSMN1; SMN2GAATSHR | |
| SCHEMBL6065515 | 0.73 | CES2 (0.37) | LMNAMAPTSMN1; SMN2TSHRHTT | |
| SCHEMBL15381249 | 0.73 | LMNA (0.61) | LMNAMAPTSMN1; SMN2SLC6A3 | |
| SCHEMBL8188595 | 0.71 | CYP1A2 (0.54) | LMNAGAATSHRSLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292283-A1 | NOVEL PHENYL-ACETAMIDE AND PHENYL-PROPIONAMIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-11-18 | — | — | US | claimed |
| EP-2225214-A1 | NOVEL PHENYL-ACETAMIDE AND PHENYL-PROPIONAMIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS | NeuroSearch AS (DK) | 2010-09-08 | — | — | EP | claimed |
| WO-2009068557-A1 | NOVEL PHENYL-ACETAMIDE AND PHENYL-PROPIONAMIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2009-06-04 | — | — | WO | claimed |
| US-20100292283-A1 | NOVEL PHENYL-ACETAMIDE AND PHENYL-PROPIONAMIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-11-18 | — | — | US | disclosed |
| EP-2225214-A1 | NOVEL PHENYL-ACETAMIDE AND PHENYL-PROPIONAMIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS | NeuroSearch AS (DK) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009068557-A1 | NOVEL PHENYL-ACETAMIDE AND PHENYL-PROPIONAMIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292283-A1 | NOVEL PHENYL-ACETAMIDE AND PHENYL-PROPIONAMIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS | KCNN2, KCNN1, KCNN3 | LMNA 2601/4885MAPT 1200/4885SMN1; SMN2 2202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.